Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration

Journal of Neuroimmune Pharmacology

Volumn 10, Issue 3, 2015, Pages 425-434

  McClay, Joseph L ^a   Vunck, Sarah A ^a   Batman, Angela M ^a   Crowley, James J ^b   Vann, Robert E ^a   Beardsley, Patrick M ^a   van den Oord, Edwin J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Metabolomics; Myelin; Sphingolipids

Indexed keywords

2 STEAROYL GLYCEROPHOSPHOCHOLINE; ACYLTRANSFERASE; ADENOSINE DIPHOSPHATE; GLYCEROPHOSPHORYLCHOLINE; HALOPERIDOL; LEUCINE; MYELIN; N ACETYLASPARTYLGLUTAMIC ACID; N ACETYLORNITHINE; SPHINGANINE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; SPHINGOLIPID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; DATA PROCESSING; DEMYELINATION; DRUG RELEASE; ELECTROSPRAY; FOLLOW UP; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; MICROWAVE IRRADIATION; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SCHIZOPHRENIA; SPHINGOLIPID METABOLISM; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; EXTRAPYRAMIDAL SYNDROME; LIPID METABOLISM; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRAIN; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALOPERIDOL; LIPID METABOLISM; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICE; MICE, INBRED C57BL; SPHINGOLIPIDS;

EID: 84939573128     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-015-9605-1     Document Type: Article

References (50)

1. Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ. (2010) Genome-wide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:279–282
2. Adams CE, Bergman H, Irving CB, Lawrie S (2013) Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev 11, CD003082
3. Armstrong MD (1979) N-delta-acetylornithine and S-methylcysteine in blood plasma. Biochim Biophys Acta 587:638–642
4. Benarroch EE (2008) N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 70:1353–1357
5. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, van Ommen B, Smilde AK (2006) Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 78:567–574
6. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK (2006) Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440:1073–1077
7. Crowley JJ, Adkins DE, Pratt AL, Quackenbush CR, van den Oord EJ, Moy SS, Wilhelmsen KC, Cooper TB, Bogue MA, McLeod HL, Sullivan PF (2012a) Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J 12:147–155
8. Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE, van den Oord E, Bogue MA, Yang H, Wang W, Threadgill DW, de Villena FP, McLeod HL, Sullivan PF (2012b) Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 23:322–335
9. de Graaf RA, Chowdhury GM, Brown PB, Rothman DL, Behar KL (2009) In situ 3D magnetic resonance metabolic imaging of microwave-irradiated rodent brain: a new tool for metabolomics research. J Neurochem 109:494–501
10. Dehaven CD, Evans AM, Dai H, Lawton KA (2010) Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2:9
11. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656–6667
12. Frolkis A, Knox C, Lim E, Jewison T, Law V, Hau DD, Liu P, Gautam B, Ly S, Guo AC, Xia J, Liang Y, Shrivastava S, Wishart DS (2010) SMPDB: the small molecule pathway database. Nucleic Acids Res 38:D480–487
13. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28:203–209
14. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA (2009) Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry 166:812–820
15. Glazer WM (2000) Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61(Suppl 3):16–21
16. Hastings J, de Matos P, Dekker A, Ennis M, Harsha B, Kale N, Muthukrishnan V, Owen G, Turner S, Williams M, Steinbeck C (2013) The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. Nucleic Acids Res 41:D456–463
17. Hoekstra D, Maier O, van der Wouden JM, Slimane TA, van IJzendoorn SC (2003) Membrane dynamics and cell polarity: the role of sphingolipids. J Lipid Res 44:869–877
18. Hsin-tung E, Simpson G (2000) Medication-induced movement disorders. In: Sadock BJ (ed) Comprehensive Textbook of Psychiatry Kaplan H. Lippincott, Williams & Wilkins, Philadelphia
19. Ikarashi Y, Sasahara T, Maruyama Y (1985) Postmortem changes in catecholamines, indoleamines, and their metabolites in rat brain regions: prevention with 10-kW microwave irradiation. J Neurochem 45:935–939
20. Jessen F, Fingerhut N, Sprinkart AM, Kuhn KU, Petrovsky N, Maier W, Schild HH, Block W, Wagner M, Traber F (2013) N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. Schizophr Bull 39:197–205
21. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48:653–683
22. Kolodziejczyk K, Hamilton NB, Wade A, Karadottir R, Attwell D (2009) The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 132:1496–1508
23. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lassig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962
24. Levy M, Futerman AH (2010) Mammalian ceramide synthases. IUBMB Life 62:347–356
25. Login GR, Dvorak AM (1994) Application of microwave fixation techniques in pathology to neuroscience studies: a review. J Neurosci Methods 55:173–182
26. Lopez-Munoz F, Alamo C (2009) The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull 79:130–141
27. Ma D, Guest PC, Bahn S (2009) Metabonomic studies of schizophrenia and psychotropic medications: focus on alterations in CNS energy homeostasis. Bioanalysis 1:1615–1626
28. Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55–72
29. Martin R, Sospedra M (2014) Sphingosine-1 phosphate and central nervous system. Curr Top Microbiol Immunol 378:149–170
30. McClay JL, Adkins DE, Vunck SA, Batman AM, Vann RE, Clark SL, Beardsley PM, van den Oord EJ (2013) Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure. Metabolomics 9:392–402
31. McLoughlin GA, Ma D, Tsang TM, Jones DN, Cilia J, Hill MD, Robbins MJ, Benzel IM, Maycox PR, Holmes E, Bahn S (2009) Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 8:1943–1952
32. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393–406
33. Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2:19–76
34. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L (2009) Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 37:521–535
35. Okada T, Kajimoto T, Jahangeer S, Nakamura S (2009) Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system. Cell Signal 21:7–13
36. Olszewski RT, Bzdega T, Neale JH (2012) mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr Res 136:160–161
37. Patti GJ, Yanes O, Siuzdak G (2012) Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13:263–269
38. Peluso MJ, Lewis SW, Barnes TR, Jones PB (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 200:387–392
39. Rosebush PI, Mazurek MF (1999) Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52:782–785
40. Slotte JP (2013) Biological functions of sphingomyelins. Prog Lipid Res 52:424–437
41. Soares-Weiser K, Fernandez HH (2007) Tardive dyskinesia. Semin Neurol 27:159–169
42. Suhre K et al (2011) Human metabolic individuality in biomedical and pharmaceutical research. Nature 477:54–60
43. Takanashi J, Saito S, Aoki I, Barkovich AJ, Ito Y, Inoue K (2012) Increased N-acetylaspartate in model mouse of Pelizaeus-Merzbacher disease. J Magn Reson Imaging 35:418–425
44. Turrone P, Remington G, Nobrega JN (2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 26:361–380
45. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121
46. van den Oord EJ, Sullivan PF (2003) False discoveries and models for gene discovery. Trends Genet 19:537–542
47. van der Knaap MS, Linnankivi T, Paetau A, Feigenbaum A, Wakusawa K, Haginoya K, Kohler W, Henneke M, Dinopoulos A, Grattan-Smith P, Brockmann K, Schiffmann R, Blaser S (2007) Hypomyelination with atrophy of the basal ganglia and cerebellum: follow-up and pathology. Neurology 69:166–171
48. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645
49. Xia J, Wishart DS (2011) Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 6:743–760
50. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS (2012) MetaboAnalyst 2.0–a comprehensive server for metabolomic data analysis. Nucleic Acids Res 40:W127–133